GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (STU:CXF) » Definitions » Short Percentage of Float

Chimerix (STU:CXF) Short Percentage of Float


View and export this data going back to 2014. Start your Free Trial

What is Chimerix Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Chimerix's Short Percentage of Float

For the Biotechnology subindustry, Chimerix's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimerix's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimerix's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Chimerix's Short Percentage of Float falls into.


;
;

Chimerix Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (STU:CXF) » Definitions » Short Percentage of Float
Comparable Companies
AVXL BCAX OCS DAWN RCKT QURE ABCL VIR GYRE SYRE VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
CMRX:USA CXF:Germany
Address
2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713
Website
https://www.chimerix.com
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.

Chimerix Headlines

No Headlines